Overview of pseudo-acute kidney injury Authors: Ran Jiang, Yafeng Huang, Huijuan Mao, Buyun Wu Published: 2026 ABSTRACT AbstractAcute kidney injury (AKI), a common complication among hospitalized patients, is associated with significant morbidity and mortality. Pseudo-AKI, a condition in which serum creatinine levels meet AKI diagnostic criteria despite a preserved glomerular filtration rate, presents diagnostic challenges. It is frequently misdiagnosed or overlooked in clinical practice, potentially leading to unnecessary interventions or diagnostic delays. Pseudo-AKI is caused by the derangement in pathways of creatinine metabolism and handling, including increased creatinine production, reduced tubular creatinine secretion, sampling or assay interference, and urine extravasation. In this review, we provide an overview of the definition, epidemiology, pathophysiology, mechanisms, diagnosis, and management of pseudo-AKI, with the aim of raising important scientific questions that warrant further exploration. Introduction Acute kidney injury (AKI) is highly prevalent in hospitalized patients, with an incidence of approximately 20% and a mortality rate ranging from 20% to 30% [1]. AKI is defined by a sudden decline in renal function, as evidenced by elevated renal biomarkers and/or reduced urine output. According to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, AKI is diagnosed by any of the following: an increase in serum creatinine (SCr) of ≥ 0.3 mg/dL (26.5 μmol/L) within 48 h; an increase in SCr to ≥ 1.5 times baseline, known or presumed to have occurred within the prior 7 days; or a urine output < 0.5 mL/kg/h for 6 h [2]. However, certain clinical conditions meet these diagnostic criteria, specifically an elevation in SCr, despite the absence of a true decline in glomerular filtration rate (GFR). This condition is referred to as pseudo-acute kidney injury (pseudo-AKI). It poses a particular diagnostic challenge in complex populations such as oncology patients, among whom an overall incidence of AKI was recently reported as 11.3% in nearly 70,000 cancer admissions [3]. With increasing recognition of the clinical significance of this condition, there is a growing need for reliable strategies to rapidly differentiate pseudo-AKI from true AKI. In this review, we present a focused overview of the concepts, epidemiology, pathophysiology, diagnosis, and management of pseudo-AKI, and highlight key scientific questions that warrant further investigation. Concepts and definitions The 2012 KDIGO AKI guideline defined pseudo-AKI as a condition in which SCr meets the diagnostic criteria for AKI despite the absence of actual kidney injury [2]. The guideline attributed this discrepancy mainly to laboratory measurement errors that lead to falsely elevated SCr levels. In recent years, an increasing number of reports have demonstrated that the etiology of pseudo-AKI is beyond measurement errors [4–7]. Factors such as urine extravasation/leakage and drugs that inhibit tubular creatinine secretion also contribute to this condition. Notably, a universally accepted definition for pseudo-AKI remains lacking. Previous studies have identified pseudo-AKI by reassessing GFR using alternative methods, such as cystatin C (CysC) or measured GFR (mGFR; e.g., using iohexol or iothalamate) [8,9]. Therefore, we propose a working definition for pseudo-AKI as a condition that meets the KDIGO SCr criteria for AKI (an increase in SCr of ≥ 0.3 mg/dL within 48 h or ≥ 1.5 times baseline) while GFR remains preserved (no clinically significant change: < 20% relative from baseline [10] as assessed by serum CysC or other exogenous filtration markers, with or without markers of kidney damage. This working definition requires further validation, particularly to clarify its diagnostic performance and optimal GFR thresholds, which might benefit from context-specific refinement across diverse acute settings. An important aspect of such validation may include defining a clinically meaningful discrepancy between estimated GFR based on Cystatin C (eGFRcysc) and creatinine (eGFRcr). Recent large-scale studies have increasingly adopted an absolute difference of 15 mL/min per 1.73 m2 or a relative difference of 20% between eGFRcysc and eGFRcr to define significant discordance [10,11]. This cutoff appears clinically intuitive, as it approximates a shift in CKD stage and carries strong prognostic implications for adverse outcomes [11]. However, this threshold serves only as a reference value in acute clinical scenarios. Whether this threshold can adequately distinguish pseudo-AKI from true AKI, and what thresholds are required to identify pseudo-AKI of different etiologies, both warrant further investigation. Epidemiology Currently, the epidemiology of pseudo-AKI remains poorly characterized, largely due to the lack of a standardized definition and the reliance on data derived mainly from case reports, case series, or studies limited to specific populations. Although historically considered rare, increasing evidence indicates that the true incidence may have been underestimated. Existing evidence focuses primarily on two subtypes of pseudo-AKI. For pseudo-AKI secondary to bladder rupture, a survey of 734,260 emergency department visits reported an incidence of 0.002% and a mortality rate of 6.7% [12]. A systematic review of 351 cases found a predominance among middle-aged adults, with intraperitoneal rupture present in nearly 90% of cases and an overall mortality of 15%; pelvic radiotherapy and alcohol intoxication were identified as major risk factors [13]. A recent matched study in pediatric patients with posterior urethral valves found that urinary extravasation, a subtype of pseudo-AKI, does not impact long-term kidney prognosis [14]. For drug-induced pseudo-AKI, creatinine elevations due to inhibition of tubular secretion by anticancer agents may occur in up to 20%–50% of patients [4]. A retrospective multicenter cohort study suggested two cases of pseudo-AKI in 13 AKI events among 29 patients receiving capmatinib therapy for non-small cell lung cancer [11]. A registered trial (NCT06338605) is currently evaluating the incidence of pseudo-AKI in patients with metastatic breast cancer receiving cyclin-dependent kinase (CDK) 4/6 inhibitors using CysC analysis. Pathophysiology and mechanisms Pathophysiology To accurately interpret pseudo-AKI, a comprehensive understanding of the pathways involved in creatinine metabolism is essential. Creatinine is generated from the breakdown of creatine in skeletal muscle and subsequently released into the bloodstream. It is primarily eliminated by glomerular filtration. However, a significant fraction (approximately 10% to 40%) is secreted by the proximal tubules [15]. In this process, creatinine is taken up from the blood across the basolateral membrane of proximal tubular cells, primarily via organic cation transporter 2 (OCT2), and subsequently secreted into the tubular lumen across the apical membrane by multidrug and toxin extrusion proteins (MATE1 and MATE2-K) [15]. This tubular secretion constitutes a key non-filtration pathway for creatinine excretion. SCr levels are not constant but exhibit physiological fluctuations, with variations of up to 20% observed in individuals with concentrations exceeding 1 mg/dL [16]. Four mechanisms have been proposed to underlie pseudo-AKI (Figure 1). First, increased creatinine production driven by substrate load or catabolism, as well as the misinterpretation of SCr elevations following a transiently low baseline (e.g., due to sepsis or acute muscle wasting), can mimic AKI. Second, drugs that inhibit tubular creatinine secretion can increase systemic SCr levels by 10% to 40%, thereby inducing pseudo-AKI. Third, drugs that use creatinine as a buffer can increase regional SCr, or assay interference may cause SCr to increase or baseline SCr to decrease, all of which may lead to pseudo-AKI. Finally, urinary tract injuries can cause an elevation in SCr through the peritoneal reabsorption of urinary ascites or fluid from urinomas, resulting in pseudo-AKI. Pathophysiology and causes of pseudo-AKI. *: Fenofibrate associated with pseudo-AKI may be involved with increased creatinine production and decreased tubular creatinine excretion. ALK: Anaplastic lymphoma kinase, CDK: Cyclin-dependent kinase, MATE: Multidrug and toxin extrusion protein, MET: Mesenchymal epithelial transition, OAT: Organic anion transporter, OCT: Organic cation transporter, PARP: Poly‑ADP‑ribose polymerase. Increased creatinine production Creatine is a nitrogenous acid synthesized primarily in the liver and also obtained from dietary protein. After transport to skeletal muscle, it is stored as creatine phosphate, which serves as an energy reservoir for adenosine triphosphate regeneration during muscle contraction, and is subsequently converted to creatinine through non-enzymatic dehydration. Approximately 1–2% of the total creatine pool is irreversibly converted to creatinine each day, corresponding to an average daily creatinine generation of 1–2 g in adults [17]. Exogenous creatine supplementation, heavy meat, and testosterone can lead to spurious elevations in SCr, mimicking impaired kidney function [18]. An Iranian study demonstrated that creatine supplementation, widely used among athletes and fitness enthusiasts, significantly increased SCr concentrations (155 ± 29 μmol/L in the creatine supplements group versus 56 ± 7 μmol/L in the control group) [19]. Similarly, excessive intake of cooked meat, which provides additional creatine load, has been shown to raise SCr levels [20]. In one trial involving healthy adult males, consumption of 225 g of cooked meat resulted in a 52% increase in SCr, peaking within 1.5–3.5 h and persisting for up to 24 h after the meal [20]. In addition, testosterone administration can increase skeletal muscle mass and creatinine generation, mimicking AKI in female-to-male transgender patients [21]. High-dose glucocorticoids and fenofibrate can precipitate pseudo-AKI. Glucocorticoids induce a catabolic state by inhibiting protein synthesis and stimulating protein degradation in skeletal muscle, which results in elevated SCr levels despite a concurrent increase in GFR [22,23]. One study reported that SCr increased by 10% after the administration of oral prednisone (60 mg/day) for 2 weeks [22]. Given the modest magnitude of this increase, pseudo-AKI is most likely to be identified in patients with a high baseline SCr who are treated with glucocorticoids. The mechanism of fenofibrate-related creatinine elevation is unclear, likely due to increased production, reduced tubular secretion, and decreased GFR rather than true kidney injury [24,25]. SCr increased by 20% (95% CI 16% to 24%) in fibrate users, with 9.1% demonstrating an increase in SCr level of ≥ 50% in elderly adults within 90 days of a new fibrate prescription [26]. Crucially, this effect appears reversible; after discontinuation of fenofibrate, an improvement of > 30% in estimated GFR was observed in 59% of patients with chronic kidney disease at 3 months [27]. A transient reduction in baseline SCr, as observed in conditions such as sepsis or acute muscle wasting, can yield a spurious diagnosis of KDIGO AKI when SCr subsequently rebounds toward its pre-illness level despite a preserved GFR. Experimental sepsis models have shown an approximate 30% reduction in creatinine production [28]. Among ICU survivors without AKI, the median discharge SCr was 33% lower than at admission, consistent with reduced creatinine generation [29]. The accurate incidence of such pseudo-AKI driven by baseline shifts in critical illness remains uncertain and warrants prospective studies. Decreased tubular creatinine excretion Physicians have long known that some drugs raise SCr without reducing GFR [30], as a proportion (10%–40%) of creatinine is eliminated via tubular secretion mediated by OCT2/OCT3/OAT2 on the basolateral side and MATE-1/MATE-2k on the luminal surface of tubular epithelial cells [15]. Disruption of the tubular secretion pathway by drugs can lead to an abnormal elevation of SCr levels (usually not exceeding a 40% increase) in the absence of symptoms, oliguria, metabolic acidosis, or hyperkalemia associated with AKI [31]. A recent simulation study focusing on patients on vancomycin and piperacillin-tazobactam showed that pseudonephrotoxicity rarely results in stage 2 or 3 AKI, and that creatinine elevations are unlikely to surpass a 2- to 3-fold increase [32]. Additionally, patients with decreased baseline GFR may be more predisposed to pseudo-AKI compared with those with normal baseline GFR, because an increase in SCr of 0.3 mg/dL is more easily reached despite similar inhibition percentages. Medications that reduce proximal tubular secretion of creatinine and thereby cause elevated SCr levels include cimetidine, several antibiotics (e.g., trimethoprim, piperacillin-tazobactam), antivirals (e.g., dolutegravir), antiarrhythmic drugs (e.g., dronedarone), mesenchymal–epithelial transition factor (MET) inhibitors (e.g., capmatinib [8], anaplastic lymphoma kinase inhibitors (e.g., crizotinib [33], poly-ADP-ribose polymerase (PARP) inhibitors (e.g., olaparib), human epidermal growth factor receptor 2 (HER2) inhibitors (e.g., tucatinib), BCR-ABL inhibitors, and CDK inhibitors [34,35]. This phenomenon has been formally recognized in recent consensus statements from the American Society of Onco-Nephrology (ASON) [36,37]. As the association of pseudo-AKI with anticancer drugs is not the primary focus of this review, we refer readers to recent publications for further details [4,38]. We also recommend consulting the prescribing information provided by Sponfeldner and colleagues [39]. An updated list of the reported drugs that affect creatinine excretion is provided in Table 1. Notably, some of these drugs could also contribute to true AKI. Table 1.Reported drugs that inhibit creatinine excretion.ClassDrug nameDrug indicationsMechanismsOther adverse effects on the kidneyReferenceH2RACimetidineGERD and gastric ulcersOCT2/MATE1AIN[71]AntibioticsTrimethoprimMultiple infectionsOAT2AIN, crystalluria[72–75]PyrimethamineParasitic or fungal infectionOCT2NR[76]Piperacillin- TazobactamBacterial infectionOAT1-OAT3AIN[70,77]AntiviralsDolutegravirHIV infectionOAT1NR[78,79]TelaprevirHIV infectionOCT2/OAT3NR[75]CobicistatHIV infectionOCT2/OAT3NR[15,75]RilpivirineHIV infection NR[75]RitonavirHIV, COVID-19 infectionMATE1NR[15]AntimalarialsChloroquineMalariaMATE1NR[80]PyrimethamineToxoplasmosis & malariaMATE1NR[76,81]AntiarrhythmicAmiodaroneAtrial fibrillation/flutterNRAKI[82]DronedaroneAtrial fibrillation/flutterOCT2/MATE1NR[83]Hypomethylating agentsAzacitidineMyelodysplastic syndromes and acute myeloid leukemiaNRTubular damage[84]METiCapmatinibMetastatic NSCLCMATE1/MATE2kNR[8,85] TepotinibMetastatic NSCLCOCT2/MATE1/MATE2kNR[86]ALKiLorlatinibMetastatic NSCLCNRMinimal change disease[87,88]AlectinibMetastatic NSCLCNRInterstitial nephritis[89,90]CrizotinibMetastatic NSCLCOCT2/MATE1/MATE2kAcute tubular necrosis[91,92]BrigatinibMetastatic NSCLCNRTumor lysis syndrome[88,93]CeritinibMetastatic NSCLCNRAcute tubular necrosis[90,94]EntrectinibNTRK solid tumors and ROS-1 NSCLCNRNR[88]EnsartinibNSCLCNRTumor lysis syndrome[93,95]Other tyrosine kinase inhibitorsCabozantinibAdvanced kidney, liver, and thyroid cancersMATEiNR[88]PralsetinibMetastatic RET-driven NSCLCMATEiNR[88]SelpercatinibRET-positive advanced NSCLC, thyroid cancersMATEiNR[88]PARPiVeliparibOvarian cancerOCT2NR[96,97]OlaparibBreast cancerOCT1/OCT2/MATE1/MATE2kNR[98,99]NiraparibMetastatic castration-resistant prostate cancer, Ovarian cancer transcriptMATE1/MATE2kNR[97,100]RucaparibRecurrent ovarian, fallopian tube, or primary peritoneal cancerOCT1/OCT2/MATE1/MATE2kNR[101,102]BCR-ABL inhibitorsDasatinibChronic myelogenous leukemiaNRProteinuria[103]ImatinibMulti-cancerOCT2/OCT3/MATE1/MATE2kAIN, TMA[104,105]NilotinibChronic myelogenous leukemiaNRHypertension[106]BosutinibChronic myelogenous leukemiaNRHypophosphatemia, TMA[107]CDK4/6 inhibitorsPalbociclibAdvanced or metastatic breast cancersOCT2Acute tubular necrosis[35,108,109]AbemaciclibAdvanced or metastatic breast cancersOCT2/MATE1/MATE2kAcute tubular necrosis[35,110]RibociclibAdvanced or metastatic breast cancersOCT2/MATE1Tubular injury[35,111,112]AIN: Acute interstitial nephritis, ALKi: Anaplastic lymphoma kinase inhibitors, ATN: Acute tubular necrosis, CDKi: Cyclin dependent kinase inhibitor, GERD: Gastroesophageal reflux disease, H2RA: H2-receptor antagonists, HIV: Human immunodeficiency virus, COVID-19: Corona Virus Disease 2019, METi: Mesenchymal epithelial transition inhibitors, NS: Nephrotic syndrome, NSCLC: Non-small cell lung cancer, NTRK: Neurotrophin receptor kinase, PARPi: Poly‑ADP‑ribose polymerase inhibitors, RAV: Renal arteriolar vacuolization, TKi: Tyrosine kinase inhibitors, TMA: Thrombotic microangiopathy, NR: no reports. Reported drugs that inhibit creatinine excretion. AIN: Acute interstitial nephritis, ALKi: Anaplastic lymphoma kinase inhibitors, ATN: Acute tubular necrosis, CDKi: Cyclin dependent kinase inhibitor, GERD: Gastroesophageal reflux disease, H2RA: H2-receptor antagonists, HIV: Human immunodeficiency virus, COVID-19: Corona Virus Disease 2019, METi: Mesenchymal epithelial transition inhibitors, NS: Nephrotic syndrome, NSCLC: Non-small cell lung cancer, NTRK: Neurotrophin receptor kinase, PARPi: Poly‑ADP‑ribose polymerase inhibitors, RAV: Renal arteriolar vacuolization, TKi: Tyrosine kinase inhibitors, TMA: Thrombotic microangiopathy, NR: no reports. Sampling & assay interference Specific intravenous formulations (e.g., dexamethasone, hydrocortisone, and azasetron hydrochloride) utilize creatinine as a buffer to maintain their physicochemical characteristics. Inappropriate sampling of blood specimens following administration can lead to falsely elevated SCr values [7], which can be corrected by redrawing the blood specimens. A previously reported case of pseudo-AKI exhibited an increase in SCr concentration from 0.75 mg/dL to 4.63 mg/dL after administration of dexamethasone [7]. The SCr level returned to normal after the blood sample was retaken. Currently, the Jaffe (alkaline picrate) and enzymatic methods are the two most commonly used techniques for measuring SCr. The Jaffe method is susceptible to interference from drugs and compounds with functional groups similar to creatinine. Several cephalosporin antibiotics (e.g., cefoxitin [40], cephalothin, cephaloridine) have been found to interact with the Jaffe reagent, resulting in spuriously elevated SCr determined by the Jaffe method [41]. A recent case also reported that nitromethane interferes with the Jaffe assay and leads to pseudo-AKI [42]. The enzymatic method is less prone to interference, but may be affected by dopamine, dobutamine, bilirubin, and globulin [16,43]. Furthermore, the interaction between 5-fluorouracil and creatinine amidohydrolase results in a false elevation of SCr levels when using the enzymatic method [44]. Given the frequent co-administration of 5-fluorouracil with amphotericin B, a known nephrotoxic agent, accurate differentiation of pseudo-AKI may avoid unnecessary discontinuation of antimicrobial therapy. Assay interference that can lower baseline SCr may also mimic AKI. For instance, bilirubin produces negative interference in Jaffe assays because its oxidation to biliverdin in alkaline media depresses the 510 nm signal, leading to spuriously low creatinine levels [45]. Similarly, dopamine and dobutamine infusions can cause marked negative interference in peroxidase-based enzymatic creatinine assays, particularly in the presence of trace line contamination. This can yield spuriously low SCr values, potentially underestimating levels by approximately 2 mg/dL [46,47]. Negative interference by calcium dobesilate on the enzymatic creatinine method represents a common clinical problem that has been widely recognized in China [48]. Clinicians should be aware of these patterns to prevent misclassification. Urine extravasation/leakage Urine leakage represents a unique form of pseudo-AKI, most commonly caused by bladder rupture [5,6,9,49]. These ruptures are classified as extraperitoneal (60%), intraperitoneal (30%), or mixed (10%) [50] and typically occur following trauma, surgery, or spontaneous rupture in the setting of bladder wall pathology. Traumatic rupture is relatively uncommon because of the bladder’s protected anatomical position, whereas spontaneous rupture is more often associated with pathological changes such as bladder wall thinning from voiding dysfunction, alcohol-induced damage, or reduced compliance. Spontaneous rupture typically occurs in patients with predisposing factors including pelvic radiotherapy, prior surgery, chronic alcohol abuse, prolonged bladder irrigation, childbirth, or bladder diverticula [51]. Urinary extravasation occurs in at least 30% of patients with high-grade renal trauma [52,53]. Less frequently, it may result from ureteral injury during pelvic surgery, trauma to other segments of the urinary tract, disruption at the ureteral anastomosis of a kidney transplantation (incidence 1.2% to 8.9%) [54], or posterior urethral valves [14,55]. When urine extravasates into the peritoneal cavity, ‘reverse peritoneal dialysis’ allows creatinine, urea, and other solutes to diffuse into the bloodstream, mimicking the biochemical features of AKI. Similarly, extraperitoneal leakage with localized collections (urinomas) enables systemic reabsorption of urine solutes. Unlike other pseudo-AKI mechanisms that only artifactually elevate SCr, urine leakage can reproduce many of the physiological consequences of true AKI: azotemia, metabolic acidosis, hyperkalemia, and hyperphosphatemia. In severe cases or those with delayed diagnosis, these metabolic complications may require dialysis, as documented in prior reports [9]. Diagnostic approaches Traditional approach Because pseudo-AKI occurs following derangements of creatinine metabolism pathways without reduced GFR, the traditional approach relies on alternative kidney function markers when pseudo-AKI is suspected (Figure 2). Currently, indicators used to assess kidney function include serum CysC and some exogenous filtration markers such as iothalamate and iohexol. Pseudo-AKI can be diagnosed when the eGFRcr differs significantly from that derived from other indicators. The return of SCr levels to baseline following the resolution of the underlying cause also supports the diagnosis. Traditional and novel approaches for diagnosing pseudo-AKI. Diagnosis of urine leakage can be a challenge to physicians because it shares similar biochemical patterns (azotemia, hyperkalemia and metabolic acidosis) with true AKI. A previous study summarized 44 cases of spontaneous bladder rupture and found that the average time from the initial presentation of symptoms to the first hospitalization and diagnosis was 5.4 days (ranging from 2 h to 36 days) [56]. Several case reports have diagnosed urinary ascites by examining the ascites creatinine/SCr ratio, with a value exceeding 1 being indicative of urinary ascites [9,13]. Imaging examinations such as conventional cystography, or delayed phase contrast–enhanced computed tomography are reliable for urinary ascites, simultaneously facilitating early detection of contrast extravasation and serving as a standard for assessing the efficacy of repair or catheterization [57]. Bladder ultrasound can diagnose urinary ascites by visualizing the flow of urine at the site of bladder rupture [58]; however, its diagnostic sensitivity has not been well established. Urinary ascites can also be identified via a methylene blue test [9] or surgical exploration [13]. Beyond urine leakage, diagnostic misclassification is common in other pseudo-AKI phenotypes. A diagnosis of pseudo-AKI cannot be established unless the condition is first suspected; therefore, awareness of its existence and characteristics should be an integral part of physician education regarding AKI. Clinicians must also distinguish pseudo-AKI from subclinical AKI, a condition characterized by preserved GFR but elevated biomarkers of kidney damage. Additionally, distinguishing features in creatinine trends can aid diagnosis: pseudo-AKI due to reduced creatinine excretion usually reaches a plateau or occurs without uremic complications (hyperkalemia, metabolic acidosis, azotemia and related clinical manifestations), whereas true AKI exhibits a progressive elevation in SCr and uremic complications. Timely recognition relies on clinician awareness and a structured diagnostic approach (Figure 3). Concise clinical practice flow diagram for pseudo-AKI. Novel approach The automatically calculated SCr/CysC ratio has been identified as a promising biomarker for diagnosing all phenotypes of pseudo-AKI (Figure 2). CysC is encoded by a housekeeping gene and produced at a stable rate in most nucleated cells. With a low molecular weight (13.3 kDa), it is freely filtered by the glomerulus and subsequently almost completely reabsorbed in the proximal tubule, resulting in very low urinary concentrations in the absence of tubular injury [59]. In patients with urinary ascites, urinary CysC that enters the abdominal cavity has a negligible effect on serum CysC levels. In contrast, urinary creatinine, normally present at concentrations approximately 100-fold higher than SCr, enters the abdominal cavity via back-diffusion and can significantly increase SCr levels, thereby elevating the SCr/CysC ratio [9]. In patients with other subtypes of pseudo-AKI, the SCr/CysC ratio can also increase as SCr is influenced by the drugs or assay-related factors [38,60]. Our pilot diagnostic study preliminarily showed that SCr/CysC ratio was significantly higher in the pseudo-AKI than in the true AKI (median[IQR] 1.89 [1.32–3.28] vs. 0.78 [0.64–0.94] L/dL), and the ratio yielded promising diagnostic performance with an area under the receiver-operating-characteristic curve of 0.97 (95% CI, 0.95–1.00), while an exploratory cutoff of >1.11 L/dL provided 95% sensitivity and 91% specificity for pseudo-AKI [61]. Before the SCr/CysC ratio can be adopted in clinical practice, several critical issues must be clarified. First, the normal range of physiological variation in SCr and CysC needs to be defined, including the degree to which these biomarkers are influenced by inflammation, cancer, corticosteroid therapy, thyroid function, and changes in body weight [62]. Second, CysC exhibits inter-assay variability of up to 20% [63] across different detection methods, as well as intraindividual physiological variability of up to 8.6% [64]. The impact of variation on the diagnostic accuracy of the SCr/CysC ratio for detecting pseudo-AKI warrants careful evaluation. Third, since SCr and CysC levels differ according to sex, ethnicity, and body composition, the reliability of the SCr/CysC ratio requires validation across diverse populations. This need is further supported by a recent ASON systematic review, which highlighted the superior accuracy of combined SCr-CysC equations and called for additional studies in specific cancer populations [37]. Additional markers may aid in diagnosing a specific subtype of pseudo-AKI. Since mesothelial cells line serosal cavities but are absent from the urinary tract, their detection in urinary sediment indicates a fistulous communication between the peritoneal cavity and the urinary tract, supporting the diagnosis of pseudo-AKI caused by bladder rupture [65]. Damage biomarkers including liver-type fatty acid-binding protein (L-FABP) and neutrophil gelatinase-associated lipocalin (NGAL) may help exclude true AKI and hold theoretical diagnostic value for pseudo-AKI [66]. Urinary L-FABP, a specific biomarker for proximal tubular injury, demonstrates high predictive accuracy for established AKI phenotypes with the assay delivering results within 15 min [67]. In patients with cirrhosis, urinary NGAL provides useful auxiliary information for excluding acute tubular necrosis and distinguishing functional renal impairment from structural injury [67,68]. Whether these biomarkers hold practical diagnostic value for pseudo-AKI requires further investigation. Management and prognosis Management of pseudo-AKI should be tailored to its underlying etiology. Therapeutic strategies for urine leakage depend on the specific site and type of injury: catheter drainage is usually sufficient for most extraperitoneal bladder ruptures, whereas intraperitoneal bladder ruptures typically require surgical repair. Urinomas are managed with drainage or surgical correction of the underlying urinary tract injury, and ureteral injuries are treated with ureteral stenting or percutaneous nephrostomy followed by definitive reconstruction (e.g., ureteroneocystostomy) [50,69]. For drug-induced pseudo-AKI, discontinuation of the causative agent is generally not required if GFR remains preserved. In cases due to sampling or assay interference, SCr should be reevaluated with repeat sampling or re-assay. Typically, SCr levels can return to baseline within 2 to 3 days after removal of the causative factors in pseudo-AKI due to the metabolic kinetics of creatinine. However, misdiagnosing pseudo-AKI as true AKI carries tangible risks. Case reports document preventable harms including unnecessary kidney biopsies, temporary dialysis, and premature withdrawal of essential therapies such as anticancer agents or antibiotics [8,9,70]. Misclassification may also delay diagnosis of underlying conditions (e.g., bladder rupture) and inappropriately label patients with AKI, affecting long-term care and insurability. While broader evidence is lacking, the consistency of these reports underscores the importance of clinical recognition. Further studies are warranted to elucidate the long-term safety profile of these transient biochemical elevations. Current challenges and future directions Despite substantial recent advances in elucidating pseudo-AKI and its underlying mechanisms, rapid and accurate diagnosis of pseudo-AKI remains challenging. To minimize the risk of underdiagnosis of pseudo-AKI, future research should focus on the following areas: (1) establishing a standardized operational definition and determining the epidemiological prevalence of pseudo-AKI; prospective investigations should be conducted in broader, unselected hospitalized populations rather than being limited to cancer patients to determine its true incidence, clinical predictors, and prognostic implications; (2) providing detailed drug information regarding pseudo-deterioration of renal function, which is currently lacking for most agents [39]; (3) validating the diagnostic utility of the SCr/CysC ratio and other biomarkers including L-FABP and NGAL for pseudo-AKI, using mGFR as the reference standard to confirm preserved GFR; (4) developing automated algorithms to identify pseudo-AKI based on existing data that currently enable AKI detection; (5) promoting research and education regarding pseudo-AKI; and (6) determining the role of mGFR. Although mGFR represents the gold standard for assessing kidney function, its complexity, high cost, and limited availability restrict its routine clinical use. Future studies should focus on identifying patient populations who would most benefit from mGFR in high-stakes clinical scenarios (e.g., guiding critical drug dosing and differential diagnosis) and exploring the feasibility of simplified mGFR protocols. Conclusions Pseudo-AKI is caused by the derangements in pathways of creatinine metabolism and handling, including increased creatinine production, reduced tubular creatinine excretion, sampling or assay interference, and urine extravasation. In clinical practice, the diagnosis is frequently overlooked or delayed, potentially leading to unnecessary interventions or diagnostic delays. Clinicians need to rule out pseudo-AKI before diagnosing AKI. Misdiagnosis can be prevented by identifying the underlying cause of pseudo-AKI and using multiple indicators to evaluate kidney function. Unlike true AKI, SCr levels in pseudo-AKI typically revert to baseline rapidly upon removal of the precipitating factors. Future work should focus on the definition, epidemiology, diagnostic markers, automated diagnosis, transparent drug labeling, and education in the area of pseudo-AKI.